Genmab A/S's stock fell 5.47% today, hitting a 5-day low amid broader market weakness with the Nasdaq-100 down 0.14% and the S&P 500 down 0.02%.
The decline follows the announcement of the EPCORE DLBCL-1 trial results for Epcoritamab, which showed a significant improvement in progression-free survival (PFS) with a hazard ratio of 0.74. However, the lack of statistically significant overall survival improvement raised investor concerns, leading to a 7% drop in stock price. Despite the promising PFS results, the market reacted negatively due to the overall survival data not meeting expectations.
This situation highlights the challenges Genmab faces in gaining investor confidence despite advancements in treatment options for patients with relapsed or refractory DLBCL. The company plans to engage with global regulatory authorities to discuss future steps for Epcoritamab, which may influence its market position moving forward.
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 38.50 USD with a low forecast of 26.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 38.50 USD with a low forecast of 26.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 33.350
Low
26.00
Averages
38.50
High
48.00
Current: 33.350
Low
26.00
Averages
38.50
High
48.00
H.C. Wainwright
Buy
downgrade
$41 -> $39
2026-01-20
Reason
H.C. Wainwright
Price Target
$41 -> $39
AI Analysis
2026-01-20
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Genmab to $39 from $41 and keeps a Buy rating on the shares. The firm says that while EPCORE DLBCL-1 failed its primary endpoint, Epkinly may still gain full approval.
BofA
Buy
maintain
2026-01-19
Reason
BofA
Price Target
2026-01-19
maintain
Buy
Reason
BofA raised the firm's price target on Genmab to $38.50 from $34.70 and keeps a Buy rating on the shares. The company last week outlined a "catalyst rich" fiscal 2026, the analyst tells investors in a research note. The firm is "bullish" into Genmab's three major catalysts in 2026, seeing each offering a $2B peak sales opportunity in attractive markets.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GMAB
Unlock Now
Truist
Buy
maintain
$48
2026-01-16
Reason
Truist
Price Target
$48
2026-01-16
maintain
Buy
Reason
Truist notes Genmab reported Phase 3 results from the EPCORE DLBCL-1 trial in transplant-ineligible second-line positive diffuse large B-cell lymphoma patients. The study missed its overall survival endpoint. However, this outcome does not change the firm's view on the key frontline DLBCL study, and Truist remains optimistic for a positive read-out this year. The firm has a Buy rating on the shares with a price target of $48.
Deutsche Bank
Buy
maintain
2026-01-08
Reason
Deutsche Bank
Price Target
2026-01-08
maintain
Buy
Reason
Deutsche Bank raised the firm's price target on Genmab to DKK 2,400 from DKK 2,000 and keeps a Buy rating on the shares.
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
